Your browser is no longer supported. Please, upgrade your browser.
CLSN [NASD]
Celsion Corporation
Index- P/E- EPS (ttm)-0.73 Insider Own1.25% Shs Outstand34.11M Perf Week8.42%
Market Cap129.24M Forward P/E- EPS next Y-0.45 Insider Trans0.00% Shs Float30.50M Perf Month38.26%
Income-21.60M PEG- EPS next Q-0.13 Inst Own9.30% Short Float6.81% Perf Quarter281.48%
Sales0.50M P/S258.49 EPS this Y-14.20% Inst Trans-14.43% Short Ratio0.11 Perf Half Y100.00%
Book/sh0.55 P/B3.75 EPS next Y38.40% ROA-53.50% Target Price- Perf Year66.13%
Cash/sh- P/C- EPS next 5Y- ROE-117.20% 52W Range0.43 - 6.50 Perf YTD189.73%
Dividend- P/FCF- EPS past 5Y47.50% ROI-76.80% 52W High-68.31% Beta2.24
Dividend %- Quick Ratio3.70 Sales past 5Y0.00% Gross Margin- 52W Low378.51% ATR0.43
Employees29 Current Ratio3.70 Sales Q/Q0.00% Oper. Margin- RSI (14)53.77 Volatility17.85% 15.78%
OptionableYes Debt/Eq0.27 EPS Q/Q6.40% Profit Margin- Rel Volume0.35 Prev Close2.20
ShortableYes LT Debt/Eq0.25 EarningsNov 16 BMO Payout- Avg Volume18.94M Price2.06
Recom2.00 SMA204.99% SMA5053.75% SMA20043.40% Volume6,664,650 Change-6.36%
Jul-16-20Downgrade Oppenheimer Outperform → Perform
Jul-14-20Downgrade Dawson James Buy → Neutral
Oct-04-17Upgrade Maxim Group Hold → Buy $7
Apr-10-17Resumed Rodman & Renshaw Buy $1.50
Nov-10-16Downgrade Maxim Group Buy → Hold
Jul-12-16Resumed H.C. Wainwright Buy $3
Jan-19-16Reiterated Maxim Group Buy $12 → $9
Jul-15-15Initiated Maxim Group Buy $12
Jan-10-14Resumed HC Wainwright Buy $5 → $8
Aug-16-12Reiterated Griffin Securities Buy $10 → $18
Feb-16-12Initiated Brean Murray Buy $7
Oct-26-11Initiated Rodman & Renshaw Mkt Outperform $6
Nov-11-09Initiated Needham Buy $7
Feb-26-21 08:45AM  
Feb-25-21 07:26PM  
05:00PM  
04:10PM  
02:45PM  
11:34AM  
08:45AM  
Feb-23-21 08:00AM  
Feb-22-21 07:30AM  
05:17AM  
Feb-12-21 08:30AM  
03:43AM  
Feb-11-21 08:30AM  
Feb-09-21 08:00AM  
Feb-06-21 05:16PM  
Jan-29-21 08:32AM  
Jan-28-21 08:00AM  
Jan-26-21 05:00PM  
Jan-22-21 08:40AM  
Jan-21-21 11:53PM  
10:01AM  
08:47AM  
Dec-29-20 01:20PM  
10:30AM  
09:37AM  
09:10AM  
Dec-28-20 12:55PM  
09:24AM  
Dec-26-20 09:00AM  
Dec-24-20 05:02PM  
11:00AM  
Dec-22-20 05:02PM  
Dec-19-20 01:00PM  
08:30AM  
Dec-18-20 11:49AM  
Dec-16-20 11:50PM  
05:00PM  
02:40PM  
Dec-15-20 05:02PM  
12:27PM  
Dec-14-20 08:50PM  
Dec-13-20 12:40AM  
Dec-12-20 10:00AM  
Dec-11-20 03:15PM  
08:53AM  
Dec-10-20 04:20PM  
01:25PM  
Dec-09-20 10:15PM  
05:00PM  
11:45AM  
Dec-08-20 12:16PM  
12:20AM  
Dec-07-20 11:54PM  
09:15PM  
Dec-05-20 04:07PM  
03:45PM  
Dec-03-20 05:17PM  
12:45PM  
11:30AM  
04:00AM  
Dec-02-20 07:00PM  
Dec-01-20 01:30PM  
Nov-30-20 10:47PM  
Nov-28-20 11:50PM  
Nov-27-20 03:10PM  
01:00PM  
01:20AM  
Nov-26-20 06:31PM  
10:00AM  
12:01AM  
Nov-25-20 06:30PM  
Nov-24-20 07:00PM  
07:00PM  
04:05PM  
Nov-23-20 10:30PM  
Nov-22-20 02:09AM  
Nov-20-20 06:00PM  
Nov-19-20 11:00AM  
10:02AM  
Nov-18-20 09:45PM  
08:00PM  
12:56PM  
Nov-17-20 01:10PM  
Nov-16-20 10:02PM  
09:15AM  
08:44AM  
08:30AM  
Nov-15-20 01:20PM  
Nov-14-20 04:15PM  
Nov-13-20 02:46PM  
11:00AM  
Nov-12-20 03:38PM  
02:15PM  
Nov-11-20 08:00PM  
04:41PM  
04:20PM  
02:36PM  
11:00AM  
11:00AM  
Nov-10-20 02:08PM  
Celsion Corporation, an integrated development clinical stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Martinez Alberto R JrDirectorFeb 28Buy0.905,0004,50045,000Feb 28 10:50 AM